Targeting pancreatic cancer by TAK-981: a SUMOylation inhibitor that activates the immune system and blocks cancer cell cycle progression in a preclinical model
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting pancreatic cancer by TAK-981: a SUMOylation inhibitor that activates the immune system and blocks cancer cell cycle progression in a preclinical model
Authors
Keywords
-
Journal
GUT
Volume -, Issue -, Pages gutjnl-2021-324834
Publisher
BMJ
Online
2022-01-25
DOI
10.1136/gutjnl-2021-324834
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Discovery of TAK-981, a First-in-Class Inhibitor of SUMO-Activating Enzyme for the Treatment of Cancer
- (2021) Steven P. Langston et al. JOURNAL OF MEDICINAL CHEMISTRY
- Integrated analysis of multimodal single-cell data
- (2021) Yuhan Hao et al. CELL
- A small-molecule SUMOylation inhibitor activates antitumor immune responses and potentiates immune therapies in preclinical models
- (2021) Eric S. Lightcap et al. Science Translational Medicine
- Cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- SUMO pathway inhibition targets an aggressive pancreatic cancer subtype
- (2020) Alexander Biederstädt et al. GUT
- B cell–Derived IL35 Drives STAT3-Dependent CD8+ T-cell Exclusion in Pancreatic Cancer
- (2020) Bhalchandra Mirlekar et al. Cancer Immunology Research
- The SUMO pathway in pancreatic cancer: insights and inhibition
- (2020) Christian Schneeweis et al. BRITISH JOURNAL OF CANCER
- Regulatory B cells in cancer
- (2020) Daniel Michaud et al. IMMUNOLOGICAL REVIEWS
- GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis
- (2019) Zefang Tang et al. NUCLEIC ACIDS RESEARCH
- MULTI-seq: sample multiplexing for single-cell RNA sequencing using lipid-tagged indices
- (2019) Christopher S. McGinnis et al. NATURE METHODS
- Metascape provides a biologist-oriented resource for the analysis of systems-level datasets
- (2019) Yingyao Zhou et al. Nature Communications
- The poly-SUMO2/3 protease SENP6 enables assembly of the constitutive centromere-associated network by group deSUMOylation
- (2019) Frauke Liebelt et al. Nature Communications
- SUMO2 and SUMO3 redundantly prevent a noncanonical type I interferon response
- (2018) John T. Crowl et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- SUMO targets the APC/C to regulate transition from metaphase to anaphase
- (2018) Karolin Eifler et al. Nature Communications
- IL-35 hinders endogenous anti-tumor T cell immunity and responsiveness to immunotherapy in pancreatic cancer
- (2018) Bhalchandra Mirlekar et al. Cancer Immunology Research
- The PRIDE database and related tools and resources in 2019: improving support for quantification data
- (2018) Yasset Perez-Riverol et al. NUCLEIC ACIDS RESEARCH
- Probing the roles of SUMOylation in cancer cell biology by using a selective SAE inhibitor
- (2017) Xingyue He et al. Nature Chemical Biology
- Massively parallel digital transcriptional profiling of single cells
- (2017) Grace X. Y. Zheng et al. Nature Communications
- SUMO-interacting motifs (SIMs) in Polo-like kinase 1-interacting checkpoint helicase (PICH) ensure proper chromosome segregation during mitosis
- (2016) Vinidhra Sridharan et al. CELL CYCLE
- The implication of SUMO in intrinsic and innate immunity
- (2016) Zara Hannoun et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Genetics and biology of pancreatic ductal adenocarcinoma
- (2016) Haoqiang Ying et al. GENES & DEVELOPMENT
- Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer
- (2016) Yaqing Zhang et al. GUT
- Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy
- (2016) Hong Jiang et al. NATURE MEDICINE
- The Perseus computational platform for comprehensive analysis of (prote)omics data
- (2016) Stefka Tyanova et al. NATURE METHODS
- The MaxQuant computational platform for mass spectrometry-based shotgun proteomics
- (2016) Stefka Tyanova et al. Nature Protocols
- A comprehensive compilation of SUMO proteomics
- (2016) Ivo A. Hendriks et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- The STRING database in 2017: quality-controlled protein–protein association networks, made broadly accessible
- (2016) Damian Szklarczyk et al. NUCLEIC ACIDS RESEARCH
- From bench to bedside a comprehensive review of pancreatic cancer immunotherapy
- (2016) Paul R. Kunk et al. Journal for ImmunoTherapy of Cancer
- Exclusion of T Cells From Pancreatic Carcinomas in Mice Is Regulated by Ly6Clow F4/80+ Extratumoral Macrophages
- (2015) Gregory L. Beatty et al. GASTROENTEROLOGY
- Knockdown of SUMO-activating enzyme subunit 2 (SAE2) suppresses cancer malignancy and enhances chemotherapy sensitivity in small cell lung cancer
- (2015) Xiaoke Liu et al. Journal of Hematology & Oncology
- Sumoylation coordinates the repression of inflammatory and anti-viral gene-expression programs during innate sensing
- (2015) Adrien Decque et al. NATURE IMMUNOLOGY
- Oncogenesis driven by the Ras/Raf pathway requires the SUMO E2 ligase Ubc9
- (2015) Bing Yu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- SUMO-mediated regulation of DNA damage repair and responses
- (2015) Prabha Sarangi et al. TRENDS IN BIOCHEMICAL SCIENCES
- SUMOylation-Mediated Regulation of Cell Cycle Progression and Cancer
- (2015) Karolin Eifler et al. TRENDS IN BIOCHEMICAL SCIENCES
- Characterization of the Loss of SUMO Pathway Function on Cancer Cells and Tumor Proliferation
- (2015) Xingyue He et al. PLoS One
- Myc-induced SUMOylation is a therapeutic vulnerability for B-cell lymphoma
- (2014) A. Hoellein et al. BLOOD
- CSF1/CSF1R Blockade Reprograms Tumor-Infiltrating Macrophages and Improves Response to T-cell Checkpoint Immunotherapy in Pancreatic Cancer Models
- (2014) Y. Zhu et al. CANCER RESEARCH
- Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer
- (2014) Avnish Kapoor et al. CELL
- SUMO2 is essential while SUMO3 is dispensable for mouse embryonic development
- (2014) L. Wang et al. EMBO REPORTS
- Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity
- (2014) Ingunn M Stromnes et al. GUT
- Identification of New Mechanisms of Cellular Response to Chemotherapy by Tracking Changes in Post-Translational Modifications by Ubiquitin and Ubiquitin-Like Proteins
- (2014) Thomas Bonacci et al. JOURNAL OF PROTEOME RESEARCH
- NOTCH1 activation in breast cancer confers sensitivity to inhibition of SUMOylation
- (2014) M P Licciardello et al. ONCOGENE
- Immunotherapy Converts Nonimmunogenic Pancreatic Tumors into Immunogenic Foci of Immune Regulation
- (2014) E. R. Lutz et al. Cancer Immunology Research
- PIAS4 is an activator of hypoxia signalling via VHL suppression during growth of pancreatic cancer cells
- (2013) W Chien et al. BRITISH JOURNAL OF CANCER
- Delineation of antigen-specific and antigen-nonspecific CD8+ memory T-cell responses after cytokine-based cancer immunotherapy
- (2012) J. K. Tietze et al. BLOOD
- Protein Group Modification and Synergy in the SUMO Pathway as Exemplified in DNA Repair
- (2012) Ivan Psakhye et al. CELL
- SUMOylation in Control of Accurate Chromosome Segregation during Mitosis
- (2012) Jun Wan et al. CURRENT PROTEIN & PEPTIDE SCIENCE
- Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice
- (2012) Meredith A. Collins et al. JOURNAL OF CLINICAL INVESTIGATION
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pancreatic ductal cells in development, regeneration, and neoplasia
- (2011) Maximilian Reichert et al. JOURNAL OF CLINICAL INVESTIGATION
- A SUMOylation-Dependent Transcriptional Subprogram Is Required for Myc-Driven Tumorigenesis
- (2011) J. D. Kessler et al. SCIENCE
- Peptide Vaccination after T-Cell Transfer Causes Massive Clonal Expansion, Tumor Eradication, and Manageable Cytokine Storm
- (2010) L. V. Ly et al. CANCER RESEARCH
- Expression analysis of Ubc9, the single small ubiquitin-like modifier (SUMO) E2 conjugating enzyme, in normal and malignant tissues
- (2010) Stergios J. Moschos et al. HUMAN PATHOLOGY
- Molecular mechanisms of micronucleus, nucleoplasmic bridge and nuclear bud formation in mammalian and human cells
- (2010) M. Fenech et al. MUTAGENESIS
- The SUMO pathway: emerging mechanisms that shape specificity, conjugation and recognition
- (2010) Jaclyn R. Gareau et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Principles of ubiquitin and SUMO modifications in DNA repair
- (2009) Steven Bergink et al. NATURE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now